Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 228
- Registration Number
- NCT00191386
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wakayama, Japan
Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome
- Conditions
- Failure to Thrive
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 75
- Registration Number
- NCT00190658
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States
Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 49
- Registration Number
- NCT00192036
- Locations
- 🇧🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turnhout, Belgium
Growth Hormone Treatment in Short Children Born Small for Gestational Age
- Conditions
- Infant, Small for Gestational Age
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-06-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00191529
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Koln, Germany
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
- Conditions
- Attention Deficit Hyperactivity DisorderComorbid Social Anxiety Disorder
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-06-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 440
- Registration Number
- NCT00190879
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio Piedras, Puerto Rico
A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
- Conditions
- Breast CancerEndometrial CancerOvarian Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT00190697
- Locations
- 🇺🇸
For information regarding investigative sites for this clinical trial, call 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or contact your personal physician, Houston, Texas, United States
Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents
- Conditions
- Breast Neoplasms
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-05-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT00191438
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nottingham City, Nottinghamshire, United Kingdom
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
- Conditions
- Superficial Bladder Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-05-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT00192049
- Locations
- 🇮🇱
For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Tel hashomer, Israel
Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature
- Conditions
- Growth Disorder
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-03-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 11
- Registration Number
- NCT00191074
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents
- Conditions
- Attention Deficit Hyperactivity Disorder
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-03-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00191659
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Basingstoke, Hampshire, United Kingdom